Rarity Bioscience at the Nordic Precision Medicine Forum

Rarity Bioscience’s Linus Bosaeus and Feri Shahin was at the Nordic Precision Medicine Forum in Stockholm, to present the engaging study Ultra-sensitive Monitoring of Minimal Residual Disease (MRD) for Cancer Patients, using superRCA Mutation Assays with Flow Cytometry Readout that highlights the latest advancements in precision oncology. 

superRCA vs the traditional routine

Testing for solid tumors often require invasive procedures like tissue biopsies, sometimes from difficult areas such as the brain. Rarity Bioscience aspires to change that with its superRCA technology, where a simple blood biopsy could suffice instead. Analyzing the circulating tumor DNA (ctDNA) in blood plasma, this novel method could offer a non-invasive, efficient approach, simplifying workflows and providing patients with quicker, more affordable, and accessible testing options.

Traditional methods often require bone marrow or tissue biopsy.

Blood sample for diagnosis

Liquid Biopsy and tissue rescue_Rarity Bioscience

Read more about the possibilities and improved monitoring:

An ultra-sensitive testing technology

The superRCA’s unparalleled ultra-sensitive capabilities enable the detection of even single nucleotide mutations, with a sensitivity of 1 mutation in 100,000 wild types. This is typically 10-100 times more sensitive for these applications than gold standard technologies like qPCR, ddPCR, NGS, and traditional liquid biopsy assays. 

Read more about the technology:

Poster Presentation

We feel proud to have attended the conference and the study we presented on Colorectal Cancer patients. In our latest publication, we have demonstrated our assay’s sensitivity in detecting mutations from liquid biopsy materials like blood samples with multiplex capabilities.

If you are interested in knowing how you can run our superRCA assay in your project, get in touch!
We would love to hear from you!

Linus Presenting the Poster at the Nordic Precision Medicine Conference
Linus Bosaeus at the Nordic Precision Medicine Forum

Share this article

Recommended articles

Rarity Bioscience at the CYTO 2024 Conference

Rarity Bioscience’s Linus Bosaeus and Lei Chen was at the CYTO 2024 Conference in Edinburgh, to present the study Ultra-sensitive Molecular MRD on Flow Cytometer using superRCA Mutation Assay, showcasing our new ultra-sensitive mutation detection technology superRCA.

Read more »

Rarity Bioscience at the Nordic Precision Medicine Forum

Rarity Bioscience was at the Nordic Precision Medicine Forum, presenting an engaging study that highlights the latest advancements in precision oncology: ”Ultra-sensitive Monitoring of Minimal Residual Disease (MRD) for Cancer Patients, using superRCA Mutation Assays with Flow Cytometry Readout”

Read more »